Cargando…
Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay
Peritoneal dissemination is a major cause of recurrence in patients with malignant tumors in the peritoneal cavity. Effective anticancer agents and treatment protocols are necessary to improve outcomes in these patients. However, previous studies using mouse models of peritoneal dissemination have n...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814254/ https://www.ncbi.nlm.nih.gov/pubmed/26716425 http://dx.doi.org/10.1111/cas.12872 |
_version_ | 1782424398746091520 |
---|---|
author | Takahashi, Ryo Yokobori, Takehiko Osone, Katsuya Tatsuki, Hironori Takada, Takahiro Suto, Toshinaga Yajima, Reina Kato, Toshihide Fujii, Takaaki Tsutsumi, Souichi Kuwano, Hiroyuki Asao, Takayuki |
author_facet | Takahashi, Ryo Yokobori, Takehiko Osone, Katsuya Tatsuki, Hironori Takada, Takahiro Suto, Toshinaga Yajima, Reina Kato, Toshihide Fujii, Takaaki Tsutsumi, Souichi Kuwano, Hiroyuki Asao, Takayuki |
author_sort | Takahashi, Ryo |
collection | PubMed |
description | Peritoneal dissemination is a major cause of recurrence in patients with malignant tumors in the peritoneal cavity. Effective anticancer agents and treatment protocols are necessary to improve outcomes in these patients. However, previous studies using mouse models of peritoneal dissemination have not detected any drug effect against peritoneal micrometastasis. Here we used the luciferase assay to evaluate peritoneal micrometastasis in living animals and established an accurate mouse model of early peritoneal microdissemination to evaluate tumorigenesis and drug efficacy. There was a positive correlation between luminescence intensity in in vivo luciferase assay and the extent of tumor dissemination evaluated by ex vivo luciferase assay and mesenteric weight. This model has advantages over previous models because optimal luciferin concentration without cell damage was validated and peritoneal microdissemination could be quantitatively evaluated. Therefore, it is a useful model to validate peritoneal micrometastasis formation and to evaluate drug efficacy without killing mice. |
format | Online Article Text |
id | pubmed-4814254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48142542016-04-11 Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay Takahashi, Ryo Yokobori, Takehiko Osone, Katsuya Tatsuki, Hironori Takada, Takahiro Suto, Toshinaga Yajima, Reina Kato, Toshihide Fujii, Takaaki Tsutsumi, Souichi Kuwano, Hiroyuki Asao, Takayuki Cancer Sci Original Articles Peritoneal dissemination is a major cause of recurrence in patients with malignant tumors in the peritoneal cavity. Effective anticancer agents and treatment protocols are necessary to improve outcomes in these patients. However, previous studies using mouse models of peritoneal dissemination have not detected any drug effect against peritoneal micrometastasis. Here we used the luciferase assay to evaluate peritoneal micrometastasis in living animals and established an accurate mouse model of early peritoneal microdissemination to evaluate tumorigenesis and drug efficacy. There was a positive correlation between luminescence intensity in in vivo luciferase assay and the extent of tumor dissemination evaluated by ex vivo luciferase assay and mesenteric weight. This model has advantages over previous models because optimal luciferin concentration without cell damage was validated and peritoneal microdissemination could be quantitatively evaluated. Therefore, it is a useful model to validate peritoneal micrometastasis formation and to evaluate drug efficacy without killing mice. John Wiley and Sons Inc. 2016-02-09 2016-03 /pmc/articles/PMC4814254/ /pubmed/26716425 http://dx.doi.org/10.1111/cas.12872 Text en © 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Takahashi, Ryo Yokobori, Takehiko Osone, Katsuya Tatsuki, Hironori Takada, Takahiro Suto, Toshinaga Yajima, Reina Kato, Toshihide Fujii, Takaaki Tsutsumi, Souichi Kuwano, Hiroyuki Asao, Takayuki Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay |
title | Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay |
title_full | Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay |
title_fullStr | Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay |
title_full_unstemmed | Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay |
title_short | Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay |
title_sort | establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814254/ https://www.ncbi.nlm.nih.gov/pubmed/26716425 http://dx.doi.org/10.1111/cas.12872 |
work_keys_str_mv | AT takahashiryo establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT yokoboritakehiko establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT osonekatsuya establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT tatsukihironori establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT takadatakahiro establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT sutotoshinaga establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT yajimareina establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT katotoshihide establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT fujiitakaaki establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT tsutsumisouichi establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT kuwanohiroyuki establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay AT asaotakayuki establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay |